Senores Pharmaceuticals Ltd

Tue 1/09/2026,15:59:19 | NSE : SENORES

₹1454.7021.90 (1.53%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 1442.30

Previous Close

₹ 1432.80

Volume

492855

Mkt Cap ( ₹ Cr)

₹ 6699.42

High

₹ 1469.90

Low

₹ 1424.30

52 Week High

₹ 1599.00

52 Week Low

₹ 662.45

Book Value Per Share

₹ 209.33

Dividend Yield

0.00

Face Value

₹ 10.00

What's Your Call?

Collective community sentiment on Senores Pharmaceuticals Ltd

Your Vote -

Buy

66.67%

Hold

25.00%

Sell

8.33%

66.67%

12 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

1454.70

383

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

383

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Senores Pharmaceuticals Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    27 Aug 2026, 12:47PM Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Senores Pharma. - Copy of Newspaper Publication

    27 Aug 2026, 11:57AM Senores Pharmaceuticals Limited has informed the Exchange regarding copy of newspaper publication for pre dispatch of Annual Report for the forthcomin

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    27 Aug 2026, 12:45PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on September 02, 2026

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    26 Aug 2026, 7:02PM Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Independent Director

  • Senores Pharma. - Appointment of Company Secretary and Compliance Officer

    26 Aug 2026, 6:59PM Senores Pharmaceuticals Limited has informed the Exchange regarding appointment of Company Secretary and Compliance Officer of the Company

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Acquisition

    26 Aug 2026, 6:58PM Senores Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of Subsidiary Company in Canada

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Acquisition

    26 Aug 2026, 6:56PM Senores Pharmaceuticals Limited has informed the Exchange regarding proposed incorporation of Wholly owned subsidiary in Mexico

  • Senores Pharma. - Board Meeting Outcome for Senores Pharmaceuticals Limited Has Informed The Exchange Regarding Outcome Of Bo

    26 Aug 2026, 6:54PM Senores Pharmaceuticals Limited has informed the Exchange about Outcome of Board Meeting held on August 26, 2026

  • Senores Pharma. - Updates

    26 Aug 2026, 6:50PM Senores Pharmaceuticals Limited has informed the Exchange regarding ' Authority to determine materiality of an event or information and disclosure to

  • Senores Pharma. - Outcome of Board Meeting

    26 Aug 2026, 6:50PM Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 26, 2026.

  • Senores Pharma. - General Updates

    26 Aug 2026, 6:50PM Proposed incorporation of a Subsidiary Company in Canada

  • Senores Pharma. - Appointment

    26 Aug 2026, 6:50PM Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Mrs Shilpa Sharma as Company Secretary & Compliance Officer of the

  • Senores Pharma. - Giving guarantees/indemnity/ becoming a surety for third party

    24 Aug 2026, 5:47PM Senores Pharmaceuticals Limited has informed the Exchange regarding giving corporate guarantee for credit facilities availed by Apnar Pharma Private L

  • Senores Pharma. - Intimation For Giving Corporate Guarantee For Credit Facilities Availed By Apnar Pharma Private Limited, Su

    24 Aug 2026, 5:43PM Senores Pharmaceuticals Limited has informed the Exchange regarding giving corporate guarantee for credit facilities availed by Apnar Pharma Private L

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    20 Aug 2026, 6:36PM Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    20 Aug 2026, 6:35PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/ Institutional Investor Meet scheduled to be held on August 25, 2026

  • Senores Pharma. - Shareholders meeting

    4 Aug 2026, 5:55PM Senores Pharmaceuticals Limited has submitted the Exchange regarding Outcome of Postal Ballot and Scutinizer Report dated August 04, 2026

  • Senores Pharma. - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    4 Aug 2026, 5:52PM Senores Pharmaceuticals Limited has informed the Exchange regarding the Scrutinzer Report dated August 04, 2026

  • Senores Pharma. - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    4 Aug 2026, 5:49PM Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Postal Ballot

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    3 Aug 2026, 3:23PM Senores Pharmaceuticals Limited has informed the Exchange regarding Transcript of Earnings Conference Call held on Monday, July 27, 2026 for Q1FY27.

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Earnings Call Transcript

    3 Aug 2026, 3:18PM Senores Pharmaceuticals Limited has informed the Exchange regarding Transcript of Earnings Conference Call held on Monday, July 27, 2026 for Q1FY27.

  • Senores Pharma. - Copy of Newspaper Publication

    28 Jul 2026, 10:38AM Senores Pharmaceuticals Limited has informed the Exchange regarding Newspaper Publication Extracts of Unaudited Financial Results of the Company for

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

    27 Jul 2026, 7:27PM Senores Pharmaceuticals Limited has informed the Exchange regarding Audio recording of Earnings Conference Call for the quarter ended June 30, 2026

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    27 Jul 2026, 7:20PM Senores Pharmaceuticals Limited has informed the Exchange regarding Audio recording of Earnings Conference Call for the quarter ended June 30, 2026

  • Senores Pharma. - Statement of deviation(s) or variation(s) under Reg. 32

    27 Jul 2026, 5:49PM Senores Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32

  • Senores Pharma. - Statement of deviation(s) or variation(s) under Reg. 32

    27 Jul 2026, 5:40PM Senores Pharmaceuticals Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32

  • Senores Pharma. - Monitoring Agency Report

    27 Jul 2026, 5:28PM Senores Pharmaceuticals Limited has informed Exchange regarding Monitoring Agency Report for quarter ended June 30, 2026

  • Senores Pharma. - Investor Presentation

    27 Jul 2026, 3:53PM Senores Pharmaceuticals Limited has informed the Exchange about Investor Presentation

  • Senores Pharma. - Press Release

    27 Jul 2026, 3:45PM Senores Pharmaceuticals Limited has informed the Exchange regarding a Media Release dated July 27, 2026

  • Senores Pharma. - Appointment

    27 Jul 2026, 3:35PM Senores Pharmaceuticals Limited has informed the Exchange regarding Appointment of Ms Anjali Shah as Assistant Vice President- Finance categorized as

  • Senores Pharma. - Outcome of Board Meeting

    27 Jul 2026, 3:18PM Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on July 27, 2026.

  • Senores Pharma. - Outcome of Board Meeting

    27 Jul 2026, 3:17PM Senores Pharmaceuticals Limited has submitted to the Exchange outcome of Board Meeting dated July 27, 2026

  • Senores Pharma. - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Raised Through Preferential Issue

    27 Jul 2026, 5:53PM Senores Pharmaceuticals Limited has informed the Exchange regarding submission of statement of deviation or variation in utilisation of funds raised t

  • Senores Pharma. - Submission Of Statement Of Deviation Or Variation In Utilisation Of Funds Of Public Issue For Quarter Ended

    27 Jul 2026, 5:41PM Senores Pharmaceuticals Limited has informed the Exchange regarding submission of statement of deviation or variation in utilisation of funds of publi

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

    27 Jul 2026, 5:32PM Senores Pharmaceuticals Limited has informed the Exchange regarding Monitoring Agency Report for quarter ended June 30, 2026

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Investor Presentation

    27 Jul 2026, 3:55PM Senores Pharmaceuticals Limited has informed the exchange regarding Investor Presentation for Q1FY27

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Press Release / Media Release

    27 Jul 2026, 3:47PM Senores Pharmaceuticals Limited has informed the exchange regarding Media Release dated July 27, 2026

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Change in Management

    27 Jul 2026, 3:40PM Senores Pharmaceuticals Limited has informed the exchange regarding Appointment of Ms Anjali Shah as Assistant Vice President - Finance categorized as

  • Senores Pharma. - Financial Results For Quarter Ended June 30, 2026

    27 Jul 2026, 3:31PM Senores Pharmaceuticals Limited has informed the exchange regarding Financial Results for quarter ended June 30, 2026

  • Senores Pharma. - Board Meeting Outcome for Outcome Of Board Meeting

    27 Jul 2026, 3:22PM Senores Pharmaceuticals Limited has informed exchange regarding Outcome of Board Meeting held on July 27, 2026

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    21 Jul 2026, 4:19PM Senores Pharmaceuticals Limited has informed the Exchange regarding Earnings Conference Call for Q1FY27 scheduled to be held on July 27, 2026 at 05:15

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    21 Jul 2026, 4:17PM Senores Pharmaceuticals Limited has informed the Exchange regarding Earnings Conference Call for Q1FY27 scheduled to be held on July 27, 2026 at 05:15

  • Senores Pharma. - Board Meeting Intimation for Considering And Approving The Unaudited Consolidated And Standalone Financial

    21 Jul 2026, 3:58PM Senores Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/07/2026 ,inter alia, to consi

  • Senores Pharma. has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2026

    20 Jul 2026, 12:50PM As of June 2026, 45.82% is owned by Promoters and 54.18% by Public. <p align=justify> Among Promoters holding, Indian Promoters holds 39.54% and Forei

  • Senores Pharma. - Submission Of Reconciliation Of Share Capital Audit Report For The Quarter Ended June 30, 2026

    7 Jul 2026, 6:57PM Senores Pharmaceuticals Limited has informed the Exchange regarding submission of Reconciliation of Share Capital Audit Report for quarter ended June

  • Senores Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Jul 2026, 6:46PM Senores Pharmaceuticals Limited has informed the Exchange regarding Submission of Reconciliation of Share Capital Audit Report for the quarter ended J

  • Senores Pharma. - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    7 Jul 2026, 4:58PM Senores Pharmaceuticals Limited has informed the Exchange regarding Certificate pursuant to Regulation 74(5) of SEBI (DP)Regulations,2018 for quarter

  • Senores Pharma. - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    7 Jul 2026, 5:07PM Senores Pharmaceuticals Limited has informed the Exchange regarding Certificate pursuant to Regulation 74(5) of SEBI (DP) Regulations, 2018 for quarte

  • Senores Pharma. - Copy of Newspaper Publication

    3 Jul 2026, 11:06AM Senores Pharmaceuticals Limited has informed the Exchange regarding copy of Newspaper Publication

  • Senores Pharma. - Shareholders meeting

    2 Jul 2026, 6:01PM Senores Pharmaceuticals Limited has informed the Exchange regarding Postal Ballot Notice

  • Senores Pharma. - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    2 Jul 2026, 5:59PM Senores Pharmaceuticals Limited has informed the Exchange regarding Postal Ballot Notice

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Jul 2026, 4:07PM Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Jul 2026, 4:05PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on July 07, 2026.

  • Senores Pharma. - Outcome of Board Meeting

    29 Jun 2026, 7:46PM Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on June 29, 2026.

  • Senores Pharma. - Board Meeting Outcome for Outcome Of Board Meeting Of The Company Held On June 29, 2026

    29 Jun 2026, 7:45PM Senores Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting of the Company held on June 29, 2026

  • Senores Pharma. - Trading Window

    26 Jun 2026, 3:48PM Senores Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regul

  • Senores Pharma. - General Updates

    10 Jun 2026, 7:18PM Senores Pharmaceuticals Limited has informed the Exchange regarding update in terms of Regulation 30(5) of SEBI (LODR) Regulations, 2015

  • Senores Pharma. - Cessation

    10 Jun 2026, 7:17PM Senores Pharmaceuticals Limited has informed the Exchange regarding Cessation of Company Secretary and Compliance Offer w.e.f. June 10, 2026

  • Senores Pharma. - Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015

    10 Jun 2026, 7:14PM Senores Pharmaceuticals Limited has informed the Exchange regarding update in terms of Regulation 30(5) of SEBI (LODR) Regulations, 2015

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

    10 Jun 2026, 7:09PM Senores Pharmaceuticals Limited has informed the Exchange regarding Cessation of Company Secretary and Compliance Offer w.e.f. June 10, 2026

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    9 Jun 2026, 11:57AM Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    9 Jun 2026, 11:55AM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on June 12, 2026.

  • Senores Pharma. - Analysts/Institutional Investor Meet/Con. Call Updates

    4 Jun 2026, 3:50PM Senores Pharmaceuticals Limited has informed the Exchange about Schedule of meet

  • Senores Pharma. - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    4 Jun 2026, 3:49PM Senores Pharmaceuticals Limited has informed the Exchange regarding Analyst/Institutional Investor meet scheduled to be held on June 09, 2026.

  • Senores Pharmaceuticals

    6 Apr 2026 , 11:07AM Senores Pharmaceuticals : The company has announced the formation of a strategic joint venture in the United States through its wholly owned subsidiary, marking a significant expansion into the federal government procurement market. This partnership strategically positions Senores to facilitate supply of its pharmaceutical product portfolio to multiple U.S. government sectors including federal government contracts, veterans affairs supply agreements, military supply contracts, and long-term national contracts. The joint venture framework provides the company with specialized credentials necessary to participate in the high-entry-barrier U.S. government procurement market, specifically targeting federal and defense needs.

  • Senores Pharmaceuticals Ltd

    12 Dec 2025 , 10:37AM Senores pharma: launches Deferiprone Tablets USP (500mg & 1000mg) in the U.S., bioequivalent to Ferriprox. Dr. Reddy’s Laboratories Inc. to market the product in the U.S. - Deferiprone Tablets had ~$70M in U.S. sales for the 12 months ending October 2025. Positive

  • Senores Pharmaceuticals

    6 Nov 2025 , 1:19PM Senores Pharmaceuticals : The company reported two major developments – Its wholly owned subsidiary, Senores Pharmaceuticals Inc. (SPI) acquired 51% stake in Zoraya Pharmaceuticals LLC, Delaware, USA through subscription of membership interest.With this move, Zoraya has become a step-down subsidiary of the Company and bolsters its operations as well as product development strengths in the US. Secondly, its material subsidiary, Havix Group Inc. D/B/A Aavis Pharmaceuticals, based in Georgia, USA, has received an Establishment Inspection Report (EIR) from the US Food and Drug Administration after a successful inspection in July 2025. The inspection concluded with three minor observations, all of which have been resolved to the satisfaction of the USFDA, marking the closure of the inspection.

  • Senores Pharmaceuticals Ltd

    13 Aug 2025 , 8:59AM Senores Pharmaceuticals, through its US subsidiary, has signed an agreement to acquire two USFDA-approved ANDAs from Teva Pharmaceuticals USA. The US market opportunity is estimated at ~USD 38 mn (IQVIA, Dec 2024) and ~USD 120 mn (Symphony, Jun 2025). The acquisition will be funded from IPO proceeds, in line with the stated IPO objectives.

  • Senores Pharmaceuticals acquires ANDA for Roflumilast

    21 Feb 2025 , 12:36PM Senores Pharmaceuticals acquires ANDA for Roflumilast 250 mcg and 500 mcg tablets
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Senores Pharmaceuticals Ltd stock 

Name March-26 March-25 March-24 March-23 March-22
Assets 821.41 801.93 260.871 99.332 48.2313
Liabilities 821.41 801.93 260.871 99.332 48.2313
Equity 46.05 46.05 30.505 9.818 8.7422
Gross Profit -18.68 -7.28 -0.062 -1.78 0.9342
Net Profit 20.25 3.69 0.814 1.199 0.293
Cash From Operating Activities -26.88 -20.4 -62.818 -43.414 -12.1977
NPM(%) 19.08 9.57 2.39 9.68 1.84
Revenue 106.09 38.54 34.006 12.382 15.8508
Expenses 124.77 45.82 34.068 14.162 14.9166
ROE(%) 2.1 0.38 0.08 0.12 0.03

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day

Peers

Other companies within the same industry or sector that are comparable to Senores Pharmaceuticals Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 871.70 -2.92 22.05 817.87 -26.19 0.57
Lotus Eye Hospital and Institute Ltd 108.77 -0.28 1553.86 2980.21 0.39 0.00
Vaishali Pharma Ltd 8.03 -0.37 25.09 18695.87 15.42 0.00
Astec Lifesciences Ltd 562.40 0.30 0.00 3193.14 -363.14 0.00

Company Info

Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.The name of the Company was thereafter changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited 2022 - Started the domestic business with a launch of the critical care injectables 2024 - Launched first CMO product in the US with Jubilant Cadista. 2025-Senores Pharmaceuticals receives Philippine FDA approval for 10 products.-The Company Acquired of 6730 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals.

Our Company was originally incorporated as "Senores Pharmaceuticals Private Limited" a private limited company under the Companies Act, 2013 through certificate of incorporation dated December 26, 2017, issued by the Registrar of Companies, Central Registration Centre.The name of the Company was thereafter changed to "Senores Pharmaceuticals Limited" upon conversion to a public limited company pursuant to a Board resolution dated August 1, 2023, a special resolution passed in the extraordinary general meeting of the Shareholders held on August 24, 2023 and the approval of the central government dated September 4, 2023, and consequently a fresh certificate of incorporation dated September 4, 2023, was issued by the RoC to reflect the change in name.Major Events and Milestones:2021- Incorporated a wholly owned subsidiary, Senores Pharmaceuticals Inc in the US.2021- Entered into a new segment of API with acquisition of Ratnagene Lifescience Private Limited 2022 - Started the domestic business with a launch of the critical care injectables 2024 - Launched first CMO product in the US with Jubilant Cadista. 2025-Senores Pharmaceuticals receives Philippine FDA approval for 10 products.-The Company Acquired of 6730 equity shares of Havix Group Inc. D/B/A Aavis Pharmaceuticals.

Parent Organisation

Senores Pharmaceuticals Ltd.

Founded

26/12/2017

Managing Director

Mr.Swapnil Jatinbhai Shah

NSE Symbol

SENORESEQ

FAQ